Orally disintegrating selegiline (Zelapar)

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00443872 (ClinicalTrials.gov)	March 2007	3/3/2007	Efficacy of Orally Disintegrating Selegilinein Parkinson's Patients Experiencing Adverse Effects Wit ...	Adding Orally Disintegrating Selegiline (Zelapar)to Patients Taking Dopamine Agonists and Experienci ...	Parkinson's Disease	Drug: orally disintegrating selegiline (Zelapar)	Parkinson's Disease and Movement Disorder Center of Boca Raton	Valeant Pharmaceuticals International, Inc.	Completed	30 Years	90 Years	All	77	Phase 4	United States
2	NCT00640159 (ClinicalTrials.gov)	January 2007	18/3/2008	Tolerability and Efficacy of Switch From Oral Selegilineto Orally Disintegrating Selegiline (Zelapar ...	Tolerability and Efficacy of Switch From Oral Selegilineto Orally Disintegrating Selegiline (Zelapar ...	Parkinson's Disease	Drug: Zelapar	Baylor College of Medicine	NULL	Completed	30 Years	90 Years	Both	55	Phase 4	United States

First Previous1Next Last